Preliminary evidence of hippocampal damage in chronic users of ecstasy

J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):83-5. doi: 10.1136/jnnp.2010.228387. Epub 2011 Mar 28.

Abstract

Various studies have shown that ecstasy (3,4-methylenedioxymethamphetamine) users display significant memory impairments, whereas their performance on other cognitive tests is generally normal. The hippocampus plays an essential role in short-term memory. There are, however, no structural human data on the effects of ecstasy on the hippocampus. The objective of this study was to investigate whether the hippocampal volume of chronic ecstasy users is reduced when compared with healthy polydrug-using controls, as an indicator of hippocampal damage. The hippocampus was manually outlined in volumetric MRI scans in 10 male ecstasy users (mean age 25.4 years) and seven healthy age- and gender-matched control subjects (21.3 years). Other than the use of ecstasy, there were no statistically significant differences between both groups in exposure to other drugs of abuse and alcohol. The ecstasy users were on average drug-free for more than 2 months and had used on average 281 tablets over the past six and a half years. The hippocampal volume in the ecstasy using group was on average 10.5% smaller than the hippocampal volume in the control group (p=0.032). These data provide preliminary evidence that ecstasy users may be prone to incurring hippocampal damage, in line with previous reports of acute hippocampal sclerosis and subsequent atrophy in chronic users of this drug.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Hallucinogens / adverse effects*
  • Hippocampus / drug effects*
  • Hippocampus / pathology
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Memory / drug effects
  • N-Methyl-3,4-methylenedioxyamphetamine / adverse effects*
  • Neuroimaging
  • Organ Size
  • Substance-Related Disorders / complications*
  • Substance-Related Disorders / pathology
  • Young Adult

Substances

  • Hallucinogens
  • N-Methyl-3,4-methylenedioxyamphetamine